We are live on ! Find out more
ADMA icon

ADMA Biologics
ADMA

72 hedge funds and large institutions have $47.3M invested in ADMA Biologics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.86% less ownership

Funds ownership: 33.46% → 32.6% (-0.86%)

20% less funds holding

Funds holding: 90 → 72 (-18)

27% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 26

30% less capital invested

Capital invested by funds: $67.7M → $47.3M (-$20.4M)

75% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 24

78% less call options, than puts

Call options by funds: $473K | Put options by funds: $2.14M

Holders
72
Holders Change
-18
Holders Change %
-20%
% of All Funds
1.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
19
Reduced
26
Closed
24
Calls
$473K
Puts
$2.14M
Net Calls
-$1.67M
Net Calls Change
+$1.11M

Top Buyers

1
BFM
Boothbay Fund Management
New York
+$4.07M
2
N
Nuveen
North Carolina
+$1.37M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$776K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$364K
5
Morgan Stanley
Morgan Stanley
New York
+$305K

Top Sellers

1
PA
Perceptive Advisors
New York
-$4.65M
2
Millennium Management
Millennium Management
New York
-$589K
3
SSA
Schonfeld Strategic Advisors
New York
-$513K
4
E
Ergoteles
New York
-$479K
5
Barclays
Barclays
United Kingdom
-$461K
Name Holding Trade Value Shares
Change 		Change in
Stake
TFIPS
76
Towarzystwo Funduszy Inwestycyjnych PZU SA
– -$108K -67,500 Closed
CSS
77
Cubist Systematic Strategies
Connecticut
– -$100K -62,484 Closed
Charles Schwab
78
Charles Schwab
California
– -$95K -58,927 Closed
LP
79
LMR Partners
United Kingdom
– -$68K -42,622 Closed
N
80
Natixis
France
– -$60K -37,200 Closed
Los Angeles Capital Management
81
Los Angeles Capital Management
California
– -$59K -37,165 Closed
YIH
82
Y-Intercept (HK)
Hong Kong
– -$27K -16,656 Closed
AGM
83
Alpine Global Management
New York
– -$17K -10,645 Closed
Citigroup
84
Citigroup
New York
– -$9K -5,327 Closed
PNC Financial Services Group
85
PNC Financial Services Group
Pennsylvania
– -$2K -1,600 Closed
CAPTRUST Financial Advisors
86
CAPTRUST Financial Advisors
North Carolina
– -$2K -1,084 Closed
PAM
87
Panagora Asset Management
Massachusetts
– -$2K -989 Closed
TRCT
88
Tower Research Capital (TRC)
New York
– -$1K -533 Closed
ASN
89
Advisory Services Network
Georgia
– -$1K -500 Closed
New York State Common Retirement Fund
90
New York State Common Retirement Fund
New York
– -$1K -478 Closed
CFFP
91
Center for Financial Planning
Michigan
– -$1K -380 Closed
1 2 3
4

ADMA Hedge Fund Activity: Q3 2021 in Review

72 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2021, worth a combined $47.3M — down 30% from $67.7M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ADMA and 6 opened new positions — a net loss of 18 holders — while 26 trimmed existing stakes and 19 added.

The largest buyer was Boothbay Fund Management, adding an estimated $4.07M. The largest seller was Perceptive Advisors, cutting an estimated $4.65M.

  • 72 institutional investors held ADMA Biologics (ADMA) as of Q3 2021, down from 90 in Q2 2021.
  • Funds reported $47.3M of ADMA Biologics stock for Q3 2021, down 30% quarter-over-quarter.
  • 6 funds opened new ADMA Biologics positions in Q3 2021 and 24 closed out, a net change of -18 holders.
  • The largest ADMA Biologics buyer in Q3 2021 was Boothbay Fund Management, an estimated $4.07M added.
  • The largest ADMA Biologics seller in Q3 2021 was Perceptive Advisors, an estimated $4.65M sold.

Based on aggregated 13F filings for Q3 2021.